Search results for "Neuroprotective agent"

showing 10 items of 156 documents

N-Acetylcysteine Amide Exerts Possible Neuroprotective Effects in Newborn Pigs after Perinatal Asphyxia

2016

<b><i>Background:</i></b> Perinatal asphyxia and ensuing reoxygenation change the antioxidant capacity of cells and organs. <b><i>Objectives:</i></b> To analyze the neuroprotective effect of the antioxidant N-acetylcysteine amide (NACA) after perinatal hypoxia-reoxygenation with an emphasis on proinflammatory cytokines and the transcription factor NF-κB in the prefrontal cortex of neonatal pigs. <b><i>Methods:</i></b> Twenty-nine newborn pigs, aged 12-36 h, were subjected to global hypoxia and hypercapnia. One sham-operated group (n = 5) and 2 experimental groups (n = 12) were exposed to 8% oxygen, until the …

Male0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesTime FactorsSwineInterleukin-1betaPharmacologyNeuroprotection03 medical and health sciences0302 clinical medicinemedicineAnimalsN-Acetylcysteine amideHypoxiaskin and connective tissue diseasesreproductive and urinary physiologyAsphyxia NeonatorumTumor Necrosis Factor-alphabusiness.industryNF-kappa BBrainmedicine.diseaseAcetylcysteinePerinatal asphyxiaOxygenAntioxidant capacityNeuroprotective Agents030104 developmental biologyAnimals NewbornAnesthesiaPediatrics Perinatology and Child Healthpopulation characteristicsFemalesense organsbusinessBiomarkers030217 neurology & neurosurgeryDevelopmental BiologyNeonatology
researchProduct

Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis

2019

International audience; Objective: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high-caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high-caloric fatty diet (HCFD) for increasing survival.Methods: A 1:1 randomized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND-NET). Eligible…

Male0301 basic medicinemortality [Amyotrophic Lateral Sclerosis]MESH: Combined Modality Therapy[SDV]Life Sciences [q-bio]law.invention0302 clinical medicineMESH: RiluzoleRandomized controlled triallawdiet therapy [Amyotrophic Lateral Sclerosis]Clinical endpointMedicineMESH: Double-Blind Methodtherapeutic use [Riluzole]MESH: Amyotrophic Lateral Sclerosismethods [Combined Modality Therapy]education.field_of_studyRiluzoleMESH: Middle AgedHazard ratioMESH: Neuroprotective AgentsMiddle Agedtherapeutic use [Neuroprotective Agents]Combined Modality Therapy3. Good healthRiluzole[SDV] Life Sciences [q-bio]Neuroprotective AgentsNeurologyMESH: Survival AnalysisFemalemedicine.drugmortality [Diet High-Fat]medicine.medical_specialtyPopulationDiet High-FatPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicineHumansddc:610educationSurvival analysisMESH: Humansdrug therapy [Amyotrophic Lateral Sclerosis]business.industryAmyotrophic Lateral SclerosisSurvival AnalysisConfidence intervalMESH: MaleMESH: Diet High-Fat030104 developmental biologyNeurology (clinical)businessMESH: Female030217 neurology & neurosurgery
researchProduct

The cognition‐enhancing activity of E1R , a novel positive allosteric modulator of sigma‐1 receptors

2013

Background and Purpose Here, we describe the in vitro and in vivo effects of (4R,5S)-2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide (E1R), a novel positive allosteric modulator of sigma-1 receptors. Experimental Approach E1R was tested for sigma receptor binding activity in a [3H](+)-pentazocine assay, in bradykinin (BK)-induced intracellular Ca2+ concentration ([Ca2+]i) assays and in an electrically stimulated rat vas deferens model. E1R's effects on cognitive function were tested using passive avoidance (PA) and Y-maze tests in mice. A selective sigma-1 receptor antagonist (NE-100), was used to study the involvement of the sigma-1 receptor in the effects of E1R. The open-field test…

MaleAgonistAllosteric modulatormedicine.drug_classSigma receptorNerve Tissue ProteinsIn Vitro TechniquesMotor ActivityPharmacologyCell LineMiceCognitionVas DeferensAllosteric RegulationIn vivoAcetamidesmedicineAnimalsReceptors sigmaCalcium SignalingRats WistarReceptorNootropic AgentsPharmacologyMice Inbred BALB CMice Inbred ICRSigma-1 receptorBehavior AnimalChemistryBrainDrug SynergismReceptor antagonistPiracetamResearch PapersCholinergic NeuronsPyrrolidinonesRacetamRatsDisease Models AnimalNeuroprotective AgentsAmnesiamedicine.drugBritish Journal of Pharmacology
researchProduct

Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice

2010

AbstractBackgroundNumerous reports indicate that MDMA users consume other psychoactive drugs, among which cannabis is one of the most common. The aim of the present study was to evaluate, using the conditioned place preference, the effect of the cannabinoid agonist WIN 55,212-2 on the rewarding effects of MDMA in mice.MethodsIn the first experiment adolescent mice were initially conditioned with 1.25, 2.5 or 5 mg/kg of MDMA or 0.1 or 0.5 mg/kg of WIN and subsequently with both drugs. Reinstatement of the extinguished preference by priming doses was performed in the groups that showed CPP. In the second experiment, animals were conditioned with 2.5 or 5 mg/kg of MDMA and, after extinction, r…

MaleAgonistCannabinoid receptormedicine.drug_classMorpholinesN-Methyl-34-methylenedioxyamphetamineCognitive Neurosciencemedicine.medical_treatmentMice Inbred StrainsNaphthalenesPharmacologylcsh:RC346-429Extinction PsychologicalMiceBehavioral NeuroscienceSerotonin AgentsPiperidinesReceptor Cannabinoid CB1RewardRimonabantConditioning Psychologicalmental disordersmedicineAnimalsDrug Interactionslcsh:Neurology. Diseases of the nervous systemBiological PsychiatryBrain ChemistryBehavior AnimalDose-Response Relationship DrugbiologyResearchMDMAGeneral MedicineExtinction (psychology)Calcium Channel Blockersbiology.organism_classificationConditioned place preferenceBenzoxazinesNeuroprotective AgentsPyrazolesCannabinoidCannabisRimonabantPsychologypsychological phenomena and processesmedicine.drugBehavioral and Brain Functions
researchProduct

Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia

2005

Background and purpose. It has been shown that the reversed operation of glutamate transporters when ATP levels fall accounts for most glutamate release induced by severe cerebral ischemia. Nitric oxide (NO) is formed after ischemia and causes ATP depletion. Our purpose is to test if NO release from inducible NO synthase (iNOS) after stroke may cause a delayed glutamate release due to ATP depletion that might underlie progression of the ischemic infarct. We have studied the effect of the highly selective inhibitor of iNOS activity 1400W on brain ATP levels, extracellular glutamate, and stroke outcome after transient focal cerebral ischemia in rats. Methods. To induce focal ischemia, the mid…

MaleBenzylaminesAmino Acid Transport System X-AGIschemiaAmidinesInfarctionDown-RegulationGlutamic AcidNitric Oxide Synthase Type IIL-argininePharmacologyNeuroprotectionNitric oxidelcsh:RC321-571chemistry.chemical_compoundAdenosine TriphosphateWestern blotmedicine.arteryStroke outcomeMedicineAnimalscardiovascular diseasesEnzyme InhibitorsRats Wistarlcsh:Neurosciences. Biological psychiatry. Neuropsychiatrymedicine.diagnostic_testbusiness.industryGlutamate receptorBrainInfarction Middle Cerebral ArteryNitric oxideCerebral Infarctionmedicine.diseaseNeuroprotectionRatsATPStrokeDisease Models AnimalNeuroprotective AgentsTreatment OutcomeNeurologychemistryCytoprotectionIschemic Attack TransientAnesthesiaMiddle cerebral arteryNitric Oxide SynthaseGlutamatebusinessNeurobiology of Disease
researchProduct

Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

2021

AbstractMotoneuronal loss is the main feature of amyotrophic lateral sclerosis, although pathogenesis is extremely complex involving both neural and muscle cells. In order to translationally engage the sonic hedgehog pathway, which is a promising target for neural regeneration, recent studies have reported on the neuroprotective effects of clobetasol, an FDA-approved glucocorticoid, able to activate this pathway via smoothened. Herein we sought to examine functional, cellular, and metabolic effects of clobetasol in a neurotoxic mouse model of spinal motoneuronal loss. We found that clobetasol reduces muscle denervation and motor impairments in part by restoring sonic hedgehog signaling and …

MaleCancer ResearchPhysiology129 StrainBiochemistryMiceDatabases GeneticMedicineMyocyteMotor NeuronsNeuronal PlasticitySkeletalSmoothened ReceptorHedgehog signaling pathwayMuscle atrophyMitochondriaAstrogliosisNeuroprotective AgentsMusclemedicine.symptomInflammation MediatorsSignal TransductionCholera ToxinMice 129 StrainhedgehogImmunologyMotor ActivityNeuroprotectionArticleDatabasesCellular and Molecular NeurosciencesmoothenedGeneticAnimalsHumansHedgehog ProteinsMuscle SkeletalHedgehogGlucocorticoidsMuscle DenervationQH573-671Animalbusiness.industryAmyotrophic Lateral SclerosisGlial biologyCell Biologymedicine.diseaseSaporinsSpineMitochondria MuscleDisease Models AnimalclobetasolinflammationCase-Control StudiesDisease ModelsDiseases of the nervous systemCytologySmoothenedbusinessEnergy MetabolismNeuroscienceOpen Field Test
researchProduct

CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity

2003

Abnormally high spiking activity can damage neurons. Signaling systems to protect neurons from the consequences of abnormal discharge activity have been postulated. We generated conditional mutant mice that lack expression of the cannabinoid receptor type 1 in principal forebrain neurons but not in adjacent inhibitory interneurons. In mutant mice,the excitotoxin kainic acid (KA) induced excessive seizures in vivo. The threshold to KA-induced neuronal excitation in vitro was severely reduced in hippocampal pyramidal neurons of mutants. KA administration rapidly raised hippocampal levels of anandamide and induced protective mechanisms in wild-type principal hippocampal neurons. These protecti…

MaleCannabinoid receptorReceptors Drugmedicine.medical_treatment2-ArachidonoylglycerolExcitotoxicityHippocampal formationmedicine.disease_causeHippocampusMicechemistry.chemical_compoundPiperidinesCannabinoid receptor type 1Excitatory Amino Acid AgonistsReceptors Cannabinoidgamma-Aminobutyric AcidMice KnockoutNeuronsKainic AcidMultidisciplinaryBrainEndocannabinoid systemNeuroprotective AgentsMitogen-Activated Protein KinasesRimonabantSignal Transductionmedicine.medical_specialtyKainic acidPolyunsaturated AlkamidesGlutamic AcidMice TransgenicArachidonic AcidsIn Vitro TechniquesBiologyGlyceridesProsencephalonInternal medicinemedicineAnimalsFuransGenes Immediate-EarlyEpilepsyCannabinoidsBrain-Derived Neurotrophic FactorExcitatory Postsynaptic PotentialsMice Inbred C57BLEndocrinologyGene Expression Regulationnervous systemchemistryMutationPyrazolesCannabinoidNeuroscienceEndocannabinoidsScience
researchProduct

Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia.

2008

The endocannabinoids anandamide (AEA) and palmitoylethanolamide (PEA) act as endogenous protective factors of the brain, using different pathways of neuroprotection against neuronal damage. Although several in vivo and in vitro studies confirmed the neuroprotective efficacy of endocannabinoids, no experimental settings compare and explore the neuroprotective potential of AEA and PEA in an acute stroke model. In this study, we investigated the neuroprotective potential by infarct measurement after high (30 mg/kg body weight) and low dosage administration (10 mg/kg body weight) of the endocannabinoid PEA in 49 male Wistar rats. In additions we studied infarct volumes of 22 male Wistar rats re…

MaleCannabinoid receptormedicine.medical_treatmentIschemiaPharmacologyNeuroprotectionBrain ischemiachemistry.chemical_compoundCannabinoid Receptor ModulatorsMedicineAnimalsRats WistarMolecular BiologyStrokePalmitoylethanolamidebusiness.industryGeneral NeuroscienceBrainRecovery of Functionmedicine.diseaseEndocannabinoid systemRatsNeuroprotective AgentschemistryIschemic Attack TransientAnesthesialipids (amino acids peptides and proteins)Neurology (clinical)CannabinoidbusinessDevelopmental BiologyEndocannabinoidsBrain research
researchProduct

Neuroprotective properties of mildronate, a mitochondria-targeted small molecule.

2010

Mildronate, a representative of the aza-butyrobetaine class of drugs with proven cardioprotective efficacy, was recently found to prevent dysfunction of complex I in rat liver mitochondria. The present study demonstrates that mildronate also acts as a neuroprotective agent. In a mouse model of azidothymidine (anti-HIV drug) neurotoxicity, mildronate reduced the azidothymidine-induced alterations in mouse brain tissue: it normalized the increase in caspase-3, cellular apoptosis susceptibility protein (CAS) and iNOS expression assessed by quantitative and semi-quantitative analysis. Mildronate also normalized the changes in cytochrome c oxidase (COX) expression, reduced the expression of glia…

MaleCell signalingAnti-HIV AgentsNitric Oxide Synthase Type IIMice Inbred StrainsMitochondrionPharmacologyNeuroprotectionElectron Transport Complex IVMiceCellular Apoptosis Susceptibility ProteinGlial Fibrillary Acidic ProteinmedicineAnimalsLymphocytesNeuroinflammationGlial fibrillary acidic proteinbiologyCaspase 3General NeuroscienceNeurodegenerationNeurotoxicityBrainmedicine.diseaseDisease Models AnimalNeuroprotective AgentsBiochemistrybiology.proteinNeurotoxicity SyndromesZidovudineCellular apoptosis susceptibility proteinMethylhydrazinesNeuroscience letters
researchProduct

Nitric oxide is involved in anoxic preconditioning neuroprotection in rat hippocampal slices.

1999

Sublethal anoxia/ischemia protects against subsequent damaging insults in intact brain or hippocampal slices. To help further understand mechanisms underlying anoxic/ischemic preconditioning, we tested three hypotheses which were that: (a) anoxic preconditioning (APC) improves electrical recovery in rat hippocampal slices; (b) anoxic preconditioning requires nitric oxide (NO); and (c) anoxic preconditioning blocks mitochondrial dysfunction that occurs following re-oxygenation after anoxia. Control hippocampal slices underwent a single 'test' anoxic insult. Experimental slices were preconditioned by 3 short anoxic insults prior to the 'test' insult. Evoked potentials (EPs), and NADH redox st…

MaleCentral nervous systemIschemiaHippocampusPharmacologyMitochondrionHippocampal formationIn Vitro TechniquesNitric OxideNeuroprotectionHippocampusNitric oxidechemistry.chemical_compoundmedicineAnimalsRats WistarHypoxia BrainIschemic PreconditioningMolecular Biologybusiness.industryGeneral Neurosciencemedicine.diseaseNADRatsmedicine.anatomical_structureNeuroprotective AgentschemistrySynapsesIschemic preconditioningNeurology (clinical)businessNeuroscienceOxidation-ReductionDevelopmental BiologyBrain research
researchProduct